Compare Incyte Corporation (INCY) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United States Natural Gas Fund — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while United States Natural Gas Fund trades at $10.19. The key difference: Incyte Corporation is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| INCY | UNG | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Commodities - Energy |
52-Week High | $129.93 | $16.90 |
52-Week Low | $81.61 | $9.63 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
UNG trades at $10.20, up 0.59% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators with mixed directional indicators. Recent news highlights natural gas price stability amid weather-driven demand fluctuations and ongoing discussions about futures versus equity exposure in the natural gas sector.
The outlook remains cautious with technical weakness offset by fundamental supply-demand dynamics. Investment opportunities exist in potential weather-driven price spikes, while risks include commodity volatility and the structural challenges of futures-based ETFs tracking spot prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
